Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1194C in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT07068906Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT1194C in B-cell non-Hodgkin lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Adverse Events (AE) after CT1194C infusion at 12 months and Maximum Tolerated Dose and/or dose range at 28 days. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
CT1194C
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07068906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07068906.